ARRIVENT BIOPHARMA, INC. Stock-Based Compensation
ARRIVENT BIOPHARMA, INC. (AVBP) reported Stock-Based Compensation of $12.15 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-12
- ARRIVENT BIOPHARMA, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $6.67M, a 101.30% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $5.49M, a 141.52% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $3.22M, a 238.45% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $3.72M, a 329.10% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $12.52M, a 290.27% increase from fiscal 2024.
- ARRIVENT BIOPHARMA, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $3.21M, a 258.44% increase from fiscal 2023.
- ARRIVENT BIOPHARMA, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $895.00K.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $12.15M 10-Q · filed 2026-08-12 | $15.37M derived: sum of 3 quarters · filed 2026-08-12 | $19.09M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $5.49M 10-Q · filed 2026-05-11 | $8.71M derived: sum of 2 quarters · filed 2026-05-11 | $12.42M derived: sum of 3 quarters · filed 2026-05-11 | $15.73M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $3.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $6.94M derived: sum of 2 quarters · filed 2026-03-05 | $10.25M derived: sum of 3 quarters · filed 2026-08-12 | $12.52M 10-K · filed 2026-03-05 |
| 2025-09-30 | $3.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $7.03M derived: sum of 2 quarters · filed 2026-08-12 | $9.30M 10-Q · filed 2025-11-10 | $10.25M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $3.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $5.58M 10-Q · filed 2026-08-12 | $6.53M derived: sum of 3 quarters · filed 2026-08-12 | $7.40M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $2.27M 10-Q · filed 2026-05-11 | $3.22M derived: sum of 2 quarters · filed 2026-05-11 | $4.09M derived: sum of 3 quarters · filed 2026-05-11 | $4.85M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $952.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.82M derived: sum of 2 quarters · filed 2026-03-05 | $2.58M derived: sum of 3 quarters · filed 2026-03-05 | $3.21M 10-K · filed 2026-03-05 |
| 2024-09-30 | $866.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $1.63M derived: sum of 2 quarters · filed 2025-11-10 | $2.26M 10-Q · filed 2025-11-10 | $2.58M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $765.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $1.39M 10-Q · filed 2025-08-11 | $1.71M derived: sum of 3 quarters · filed 2025-08-11 | $1.93M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $625.00K 10-Q · filed 2025-05-12 | $944.00K derived: sum of 2 quarters · filed 2025-05-12 | $1.16M derived: sum of 3 quarters · filed 2025-05-12 | $1.35M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $319.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $536.00K derived: sum of 2 quarters · filed 2025-03-03 | $729.00K derived: sum of 3 quarters · filed 2025-03-03 | $895.00K 10-K · filed 2025-03-03 |
| 2023-09-30 | $217.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $410.00K derived: sum of 2 quarters · filed 2024-11-14 | $576.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $193.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $359.00K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $166.00K 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |